RELPAX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Relpax, and what generic alternatives are available?
Relpax is a drug marketed by Upjohn and is included in one NDA.
The generic ingredient in RELPAX is eletriptan hydrobromide. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the eletriptan hydrobromide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Relpax
A generic version of RELPAX was approved as eletriptan hydrobromide by ZYDUS PHARMS on June 16th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RELPAX?
- What are the global sales for RELPAX?
- What is Average Wholesale Price for RELPAX?
Summary for RELPAX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 126 |
| Clinical Trials: | 3 |
| Patent Applications: | 2,953 |
| Drug Prices: | Drug price information for RELPAX |
| What excipients (inactive ingredients) are in RELPAX? | RELPAX excipients list |
| DailyMed Link: | RELPAX at DailyMed |
Recent Clinical Trials for RELPAX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 1 |
| Pfizer | Phase 1 |
| GlaxoSmithKline | Phase 3 |
Pharmacology for RELPAX
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Paragraph IV (Patent) Challenges for RELPAX
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| RELPAX | Tablets | eletriptan hydrobromide | 20 mg and 40 mg | 021016 | 1 | 2010-03-29 |
US Patents and Regulatory Information for RELPAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upjohn | RELPAX | eletriptan hydrobromide | TABLET;ORAL | 021016-001 | Dec 26, 2002 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Upjohn | RELPAX | eletriptan hydrobromide | TABLET;ORAL | 021016-002 | Dec 26, 2002 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RELPAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Upjohn | RELPAX | eletriptan hydrobromide | TABLET;ORAL | 021016-001 | Dec 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Upjohn | RELPAX | eletriptan hydrobromide | TABLET;ORAL | 021016-002 | Dec 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| Upjohn | RELPAX | eletriptan hydrobromide | TABLET;ORAL | 021016-002 | Dec 26, 2002 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RELPAX
See the table below for patents covering RELPAX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hungary | T77310 | ⤷ Sign Up | |
| Slovakia | 24897 | SALTS OF AN ANTI-MIGRAINE INDOLE DERIVATIVE | ⤷ Sign Up |
| Egypt | 23822 | Salts of an anti-migraine indole derivatives | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RELPAX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0592438 | 36/2001 | Austria | ⤷ Sign Up | PRODUCT NAME: ELETRIPTAN UND DIE PHARMAZEUTISCH VERTRAEGLICHEN SALZE DAVON, EINSCHLIESSLICH DES HYDROBROMIDS; NAT. REGISTRATION NO/DATE: 1-24155 20010801; FIRST REGISTRATION: LI 55218 01, 55218 02 20001214 |
| 0592438 | C00592438/01 | Switzerland | ⤷ Sign Up | FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH |
| 0592438 | 02C0013 | France | ⤷ Sign Up | PRODUCT NAME: ELETRIPTAN HYDROBROMIDE; NAT. REGISTRATION NO/DATE: NL 26625 20011105; FIRST REGISTRATION: LI - IKS 55218 20001214 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
